Zhou Q, Chen M, Jiang O, Pan Y, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phas Lancet Oncol 2022 Jan 14. pii: S1470-2045(21)00630.
PMID: 35038429